The Rubber Stopper on Every GLP-1 Pen

1The constraint was the vial, not the molecule

Semaglutide and tirzepatide spent 2023-25 on the FDA shortage list not because synthesis failed but because sterile fill-finish - filling cartridges and syringes, assembling auto-injector pens, releasing them under aseptic conditions - could not scale as fast as demand. Lilly and Novo have poured tens of billions into captive capacity, and Novo's parent bought a CDMO outright: Novo Holdings' $16.5 billion acquisition of Catalent, closed December 2024, was a fill-finish deal wearing an M&A press release.

Every filled unit, whoever fills it, contains the same class of component: an elastomeric stopper or plunger in contact with the drug.

2West's quiet dominance

West Pharmaceutical Services (WST), headquartered in Exton, Pennsylvania, is the dominant maker of those components - industry estimates commonly put its share of injectable elastomers around 70%, with Datwyler (Swiss, listed in Zurich) the main alternative and premium lines like NovaPure specified by name in biologic filings. The share is an estimate and we flag it below; the mechanism is not: components that touch a biologic are named in the regulatory file, and changing them means stability studies and refiling.

That is the same process-embedded lock-in as ABF in substrates or chucks in etch chambers - the moat is everyone else's paperwork.

3How the exposure actually behaves

WST's GLP-1 leverage is volumetric: pens consume plungers and stoppers per unit, so prescription trends flow through with a lag through customer inventory - which is also the risk, as 2023-24 showed when post-pandemic destocking hit the stock hard even while GLP-1 volumes grew. The honest framing: WST is a royalty on injectable volume generally, GLP-1 included, minus inventory noise.

Adjacent listed layers: glass cartridges and devices (Gerresheimer, Schott Pharma, Stevanato in Europe), bioprocessing upstream (Thermo Fisher, Danaher). The drugmakers themselves - LLY, NVO - are the demand signal.

4Watchpoints

Track: FDA shortage-list status for the incretin franchises (both cleared it as capacity landed - re-entry would signal the gate is binding again), WST's high-value product mix and destocking commentary, and capacity announcements measured in filling lines, not dollars. The falsifier for the component thesis would be a major biologic switching elastomer supplier mid-life - watch for it; we could not find a precedent, which is rather the point.

Sources and method

Compiled from public filings, government and agency data and trade press, cross-checked against our desks where they overlap. Supply shares and lead times in private industrial chains are estimates, are labelled as estimates, and the ones we could not verify this week are under what we do not know rather than asserted. The lines below are the factual spine.

• GLP-1 drugs spent 2023-25 on the FDA shortage list with fill-finish capacity the stated constraint
• Novo Holdings acquired Catalent for $16.5B (closed Dec 2024) - a fill-finish capacity acquisition
• Drug-contact elastomers are specified in regulatory filings; switching requires stability work and refiling (regulatory practice)

Underlying sources

• FDA drug shortage database (semaglutide/tirzepatide entries and resolutions)
• Novo Holdings-Catalent transaction announcements (closed December 2024)
• West Pharmaceutical disclosures; Datwyler segment reporting
• Lilly and Novo Nordisk capex announcements

Written by Parallax Research's research writer on 2026-07-29 and reviewed against the dossier it was given. Figures are as of that date and are not updated in place. Our scoring model's out-of-sample AUC is published in the whitepaper; nothing here is a forecast.